BioSpace News Archive

Business

Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today reported financial results for its fiscal year 2024 third quarter ended December 31, 2023 and provided a corporate update.

February 13, 2024

·

10 min read

Business

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2023 fourth quarter and full-year financial results on Tuesday, March 5, 2024, before the market opens.

February 13, 2024

·

3 min read

Business

Globus Medical Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call

Globus Medical, Inc., a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Tuesday, February 20, 2024.

February 13, 2024

·

4 min read

Treadwell Announces the Formation and Members of Scientific Advisory Board

Treadwell Therapeutics, a privately held clinical-stage biotechnology company pioneering and advancing novel first-in-class medicines for unmet needs in cancer, announced the formation of a Scientific Advisory Board comprised of prominent oncology leaders and drug developers.

February 13, 2024

·

7 min read

Drug Development

Global Registrational Phase III Study of Olverembatinib (HQP1351) Cleared by FDA

Ascentage Pharma announced that it has received clearance from the US Food and Drug Administration to initiate a global registrational Phase III trial of olverembatinib in previously treated adult patients with chronic-phase chronic myeloid leukemia.

February 13, 2024

·

5 min read

Pharm Country

Azitra, Inc. Announces Pricing of Public Offering - February 14, 2024

Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced the pricing of an underwritten public offering of 16,667,000 shares of common stock.

February 13, 2024

·

3 min read

Deals

MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

MyMD Pharmaceuticals, Inc.® announced today that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 30 pre-split shares.

February 13, 2024

·

5 min read

Genetown

Fall today, move tomorrow! Local news story highlights using IlluminOss to fix an older patient’s fracture to deliver fast rehabilitation instead of immobilization

IlluminOss Medical is announcing its patented, minimally-invasive technology for fracture repair in older patients was just featured on the Rhode Island Channel 10 News.

February 13, 2024

·

2 min read

BioCapital

Expert Systems Facilitates Rapid Advancement of Groundbreaking Covid-19 Treatment, TRX01, to Clinical Trials Within Two Years

Expert Systems Inc., a private company, announces the initiation of a first-in-human trial of TRX01 by their partner Trawsfynydd Therapeutics, a private company.

February 13, 2024

·

1 min read

FDA

PCA 500™-- the world’s most efficient and versatile 12-lead ECG, receives FDA clearance for use in acute care

QT Medical announces that it has received 510(k) clearance from the FDA for PCA 500™ use in acute care.

February 13, 2024

·

2 min read